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Abstract 
Objective: At present, growth factor-containing products such as enamel matrix derivatives, 
recombinant bone morphogenetic protein (rh-BMP), recombinant platelet derived growth factor and 
platelet rich plasma (PRP) have gained increasing attention. PRP is an autologous source of platelet 
growth factors used to enhance healing of soft and hard tissues. PRP has gained popularity due to its 
autologous nature, easy procurement and low cost. 
Review of Literatures: This study focuses on procurement and clinical applications of PRP. 
Conclusion: Controversy exists regarding the efficacy and applications of PRP and longitudinal 
studies are required to further elucidate this subject. 
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Dental implantation is the most commonly used 
technique for functional rehabilitation of an 
edentulous ridge. Implant treatments require 
adequate bone volume and density at the site of 
implantation. 
Guided bone regeneration (GBR) is a surgical 
technique to improve the quality and quantity of 
bone in subjects with bone defects using 
autografts, allografts, xenografts and alloplastic 
materials. Bone autografts are the most ideal 
grafts to increase bone volume. However, they 
have some disadvantages such as the need for a 
secondary surgical site (donor site), longer 
duration of surgery, greater post-operative 
patient discomfort and limited graft volume (1).  
Due to the risk of disease transmission when 
using demineralized freeze-dried bone allografts 
(DFDBA) and mineralized freeze-dried bone 
allografts (FDBA), use of xenografts and 
alloplasts has increased due to their relatively 
optimal biocompatibility, high osteoconductivity 
and to a lesser degree osteoinductivity (1). In 
order to minimize donor site trauma and not 
losing the osteoconductive property of 
autogenous bone, bone substitutes like hydroxy 
apatite (HA), tricalcium phosphate (TCP) and 
Bio-Oss in combination with autogenous bone 
have been suggested for bone grafting (2). 
Graft maturation occurs within 6-12 months 
depending on the height and quality of the 
remaining crestal bone, percentage of 
autogenous bone in composite grafts and implant 
surface texture (when implants are placed in the 
grafted area) determined by the clinician (3). 
It is beneficial for the patient to shorten this time 
period via enhancing the process of graft 
maturation. For example, when autogenous 
grafts are used alone, 4-6 months time is 
required for osseointegration of implant (in case 
of two-stage implant placement). Thus, the 
patient’s waiting time until implant loading will 
be 10-12 months. As the result, osteoinductive 
materials have gained attention to enhance the 
process of maturation and improve the quality of 
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bone (3, 4). Growth factors are now used to 
enhance bone regeneration. These factors play a 
role in chemotaxis, mitogenesis and 
differentiation of cells involved in the process of 
bone formation due to having osteoinductive 
properties. These factors have the ability to 
induce the formation of periodontal ligament 
(PDL), bone and cement when used in 
periodontal lesions (5). Platelets have alpha 
granules containing growth factors and 
accumulate in the wound area in the cellular 
phase of wound healing. Thus, PRP has attracted 
attention to enhance the process of bone graft 
healing. 
Platelet growth factors 
Growth factors are polypeptides that play a role 
in the process of chemotaxis, differentiation, 
mitogenesis and metabolism of cells involved in 
wound healing. Growth factors present in 
platelet alpha granules are as follows (1, 5-7): 
1. Platelet-derived growth factor (PDGF): 
Two-chain polypeptides contain di-sulfide 
bonds with a molecular weight of 27-30×103 
Daltons. They also exist in macrophages, 
monocytes, smooth muscle cells and 
endothelial cells in addition to platelets. 
PDGF plays a role in bone protein synthesis 
as well as in bone resorption. It is a mitogenic 
factor for mesenchymal cells (fibroblasts and 
smooth muscle cells) and has chemotactic 
properties for fibroblasts, smooth muscle 
cells, macrophages and leukocytes. It also 
possesses angiogenic properties and induces 
collagen and extracellular matrix synthesis 
(8-10). 
2. Transforming growth factor B (TGF-B): 
It is a two-chain polypeptide. The two chains 
are attached via di-sulfide bonds. Its 
molecular weight is 25,000 Daltons. Three 
different gene products of TGF-B are 
available namely TGF-B1, TGF-B2 and 
TGF-B3. TGF-B1 has the highest 
concentration in bone and platelets. TGF-B 
has autocrine and paracrine functions. Local 
effects of TGF-B on adjacent cells including 
fibroblasts, bone marrow stem cells, 
endothelial cells and preosteoblasts have been 
well documented. This growth factor plays a 
role in angiogenesis, and synthesis of 
fibronectin, glycosaminoglycans and 
collagen. One of its most important functions 
is chemotaxis and mitogenesis of pre-
osteoblastic cells. Moreover, it inhibits the 
production of osteoclasts and prevents bone 
loss (11, 12). 
3. Platelet-derived epidermal growth factor 
(PDEGF): 
This growth factor was the first growth factor 
detected by Cohen in 1962 (13). It induces 
the proliferation of keratinocytes and dermal 
fibroblasts and subsequently enhances wound 
healing. 
4. Platelet-derived angiogenesis factor (PDAF): 
This polypeptide directly or indirectly 
stimulates vascular endothelial cells and is 
released in large amounts under hypoxic 
conditions (14).  
5. Insulin-like growth factor (IGF): 
It is a single-chain polypeptide with 75,000 
Daltons molecular weight. By its paracrine 
function, it induces the growth of cartilage, 
bone matrix formation and proliferation of 
osteoblasts and pre-osteoblasts. With its 
autocrine function, it increases the activity of 
alkaline phosphatase (ALP) in osteoblasts. 
6. Platelet factor-4: With its anti-heparin 
potential, platelet factor 4 plays a chemotactic 
role for neutrophils and fibroblasts (15). The 
function of PRP is due to the presence of 
these growth factors. 
What is PRP?  
PRP is platelet-rich plasma also known as 
platelet concentrates (PCs), autogenous platelet 
gel (APG), plasma very rich in platelet (PVRP) 
and platelet rich growth factor (PRGF)(7). 
PRP gel contains high concentrations of platelet 
and natural fibrinogen to a lesser extent (Figure 
1). The properties of PRP are in fact based on 
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the production and release of several growth 
factors due to the activation of platelets. Release 
of growth factors occurs within 10 minutes from 
the onset of blood clot formation (16). By 
activation of platelets, their alpha granules are 
ruptured within 3-5 days. The released growth 
factors based on their half-life exert their 
primary proliferative effects maximally within 
10 days (1, 7).  
Normal blood platelet count is 15,000-44,000. In 
different PRP preparation systems, platelet 
concentration increases by 160-740% (17). 
Typically, to achieve the therapeutic effects of 
PRP, 400 to 500% increase in number of 
platelets (1,000,000/ml) is required (18, 19). 
 
Figure 1- PRP gel 
 
Figure 2- PRGF centrifugation 
 
PRP preparation techniques:  
PRP is basically prepared by centrifugation and 
isolation of blood components based on their 
molecular weight. 
1. General-purpose cell separator: In this 
system, similar to ELMD-500, 450 ml of 
patient blood is collected in a blood 
collection bag containing citrate-phosphate-
dextrose anticoagulant. Ethylenediamine tetra 
acetic acid (EDTA) is not used as an 
anticoagulant agent anymore because it 
disintegrates the platelets. Next, the blood is 
centrifuged in centrifugation tubes at 5,600 
rpm (20, 21). By doing so, blood components 
are separated in three layers. Red blood cells 
precipitate at the bottom. The middle layer is 
composed of PRP and the platelet poor 
plasma (PPP) comprises the supernatant. The 
PPP is discarded and the remaining two 
layers are centrifuged at a low speed of 2400 
rpm in order to isolate 30ml of PRP from the 
RBCs. In this process, PRP is prepared from 
patient blood within 30 minutes. In order to 
prepare PRP, fresh blood must be used within 
6 hours after collection (1). Number of 
platelets in the prepared PRP must be at least 
3 times their normal count in the plasma (4). 
The PRP prepared in this technique contains 
500×103 to 106 platelets/ml (1). Using this 
technique, erythrocytes and the remaining 
PPP can be returned to the patient’s 
circulation. With recent advances in 
technology, by using less volume of blood, 
higher platelet concentration is achieved and 
there is no need to return the RBCs and PPP 
to the patient’s blood circulation. 
2. Platelet concentrating cell separator: Due to 
the mentioned advantages, this technique has 
gained increasing popularity. Two of the cell 
separator systems namely HSPCS and 3i 
PCCS have been approved by the food and 
drug administration (FDA). However, 
different systems have been manufactured by 
different companies including Harvest 
SmartPrep®, Friadent-Schutze, Curasan and 
PRGF system (Figure 2)(1, 5, 22, 23). In 
these systems, larger volumes of patient 
blood are required to prepare PRP. Also, to 
prepare PRP gel, bovine thrombin is required. 
However, the PRGF system requires less 
amount of patient blood and there is no need 
for bovine thrombin. In this system, 5-40 ml 
of patient blood is collected in 5cc tubes 
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containing 3.8% trisodium citrate and 
centrifuged at 270G. By centrifugation, 
patient blood is separated into fractions as 
follows (from the bottom to the top)(Figure 
3):  
A. RBC layer 
B. 0.2 ml of plasma very rich in growth factors 
(PVRGF) located immediately above the 
RBC layer 
C. 0.3 ml of plasma rich in growth factor 
(PRGF) 
D. 0.5 ml of plasma with growth factors (PGF) 
E. 1 ml of plasma poor in growth factor 
(PPGF)(the most superficial layer) 
In this technique, the time required for 
preparation of PRGF would be 10-15 minutes 
(5). 
 
Figure 3- Separated layers following blood 
centrifugation at 270G in the PRGF system 
 
Preparation of PRP for clinical application: 
To prepare PRP gel, topical bovine thrombin 
(TBT) used to be applied; 6 ml of PRP, 1 ml of 
10% calcium chloride, 1 ml of TBT and 1 ml of 
air were mixed and stirred for a few seconds in 
order for the process of coagulation and 
subsequent gelation to be initiated. But, reports 
were published regarding the production of 
antibodies against factors V, XI and thrombin 
increasing the risk of life threatening 
coagulopathies. By 2003, 32 patients were 
reported to develop TBT-related coagulopathies. 
Thus, highly pure thrombin was produced to 
decrease the concentration of factor V to less 
than 0.2 ug/ml (1). Landesberg, et al. (2000) 
invented a new technique to activate PRP using 
ITA gelling agent; but did not report the 
composition or mechanism of action of this 
material (21). 
Marx (2000) suggested using recombinant 
human thrombin and autogenous thrombin (24). 
Kassolis, et al. (2000) used autogenous thrombin 
to activate PRP in the clinical setting (25). 
In the PRGF system, manufactured by the 
Institute of Biotechnology in Spain, only 10% 
CaCl2 is used for the activation of platelets in 
PRGF. The manufacturer claims that this system 
does not need the use of thrombin (26).  
Platelet rich fibrin was first introduced by 
Choukroun in France in 2001. The protocol of 
producing PRF is very simple. Blood sample is 
centrifuged in a 10cc tube without the 
anticoagulant at 3000 rpm for 10 minutes. 
Platelets become activated upon contact with the 
glass tube wall and release growth factors. Not 
using anticoagulants, thrombin and calcium 
chloride are among the advantages of PRF. 
Thus, in this technique, fast action is important 
for preparation of PRF (before blood 
coagulation) (27). 
Clinical applications of PRP: 
PRP is used alone or in combination with bone 
graft materials to regenerate hard tissue or as a 
barrier membrane for socket preservation 
(Figure 4), treatment of bone defects around 
immediate implants (Figure 5) or treatment of 
defects due to peri-implantitis (1). 
 
 
Figure 4A- Using PRGF gel for socket 
preservation (day of surgery) 
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Figure 4B- Using PRGF gel for socket 







Figure 5- Using a mixture of autogenous bone and 
PRGF gel in a bone defect mesial to the maxillary 
first molar (top and middle, right and left sides); 
treatment outcome after 4 months (bottom, right 
side) 
Marx, et al. reported the clinical outcome of 
PRP application in dentistry for the first time in 
1998. In their study, PRP was used to improve 
the clinical outcome of cancelous bone marrow 
graft for mandibular regeneration after tumor 
resection. The results demonstrated increased 
rate and amount of new bone formation (28). 
In 1999, Anitua used a combination of 
autogenous bone and PRP for socket grafting. 
They demonstrated better epithelialization and 
formation of more compact bone with well-
organized trabeculae in the intervention group 
compared to the control group (using only 
autogenous bone)(26). 
Kutkut, et al. (2012) in their study evaluated the 
efficacy of PRP for socket grafting and 
demonstrated a significant histomorphometric 
difference between the two groups of control 
(CollaPlug) and intervention (calcium sulfate in 
conjunction with PRP) (p<0.05). The percentage 
of newly formed bone was 66% in the 
intervention and 38% in the control group (29). 
Suba, et al. (2004) in an animal study used a 
combination of PRP and Cerasorb in the test 
side and Cerasorb alone in the control side for 
socket grafting. The histological results 
demonstrated formation of high-density new 
bone at the test side after 6 weeks. After 12 
weeks, moderate bone density at the test side 
and after 24 weeks, equal bone density at both 
sides was noted (30). 
Simon, et al. (2009) demonstrated that platelet 
rich fibrin (PRF) in comparison with DFDBA 
along with membrane is the best option for 
socket preservation. Using PRF facilitates bone 
healing and decreases the complications related 
to the use of membrane (31). 
When PRP is added to bone grafts, fibrin, 
fibronectin and other adhesion molecules form a 
scaffold with osteoconductive properties for 
bone growth. Addition of PRP gel to graft 
materials (autografts, allografts, xenografts and 
alloplasts) enriches the grafts with growth 
factors that accelerate new bone formation and 
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increase the quantity and quality of newly 
formed bone in sinus lifting, alveolar ridge 
augmentation, treatment of grade II furcation 
defects of the mandibular teeth and distraction 
steogenesis (1, 3, 5, 32, 33). Addition of PRP gel 
to graft materials gives them a putty-like 
consistency, facilitates their application to the 
respective site and increases graft stability 
(Figure 6) (5). 
 
Figure 6- Putty-like consistency of the mixture of 
PRGF gel and bone graft materials 
 
Using PRP facilitates soft tissue healing by 
speeding up revascularization, reepithelialization 
and cell proliferation after flap surgery (1). 
Thus, application of PRP to the flap margins or 
the tissue beneath the flap is recommended. 
Garg, et al. (2000) suggested using PRP-based 
resorbable membranes (34). Stenport, et al. 
(2011) reported that using PRP along with inlay 
or onlay grafts may affect bone formation in the 
grafted tissue (35). Torres, et al. (2010) 
evaluated the effect of application of PRP on 
exposure of titanium mesh. They demonstrated 
no exposure of titanium mesh in the PRP group 
and 27% exposure in the control group. 
Moreover, bone formation increased by using 
PRP (36). 
PRP has also been used for repair of intra 
osseous periodontal defects (37-52). Pradeep, et 
al. (2012) evaluated the efficacy of PRP and 
PRF for treatment of three-wall bony defects due 
to chronic periodontitis. They demonstrated 55% 
bone healing in the two groups of PRP and PRF 
compared to the control group. Based on the 
results, PRP and PRF were not significantly 
different for treatment of 3-wall periodontal 
bone defects (39). 
Sharma and Pradeep (2011) in their study 
evaluated the efficacy of PRF for treatment of 
grade II furcation defects in mandibular molars. 
Clinical and radiographic results reported the 
favorable efficacy of PRF for treatment of 
furcation defects compared to flap debridement 
alone. In their study, 5 out of 6 grade II furcation 
defects were converted to grade I as the result of 
PRF application (40). 
Del Fabrro, et al. (2011) in a review study and 
meta-analysis evaluated the role of PRP in 
surgical periodontal treatments. The results 
showed that using PRP along with graft 
materials may have positive effects on the 
results of treatment of periodontal bone lesions 
but had no efficacy for GTR. Also, it was 
demonstrated that using PRP did not have any 
significant effect on gingival recession (38). 
Powell, et al. (2009) evaluated the efficacy of 
PRP for wound healing following periodontal 
flap surgery in an animal study on mini pigs and 
demonstrated that using PRP had no effect on 
periodontal surgery wound integrity; 
histologically, no difference was noted between 
the two groups of periodontal flap alone and flap 
plus PRP (41).  
Several studies have evaluated the use of PRP 
along with graft materials for sinus graft surgery 
(39-53). Mazor, et al. (2009) in their study 
evaluated the efficacy of using PRF alone for 
sinus augmentation and demonstrated that 
application of PRF alone for sinus augmentation 
simultaneous with implantation resulted in bone 
regeneration to the implant apex both 
radiographically and histologically. They 
recommended using PRF considering its low 
cost and easy procurement as a sinus 
augmentation technique especially when sinus 
membrane preservation is indicated (53). Riaz, 
et al. (2010) demonstrated that application of 
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PRP along with an allograft for sinus grafting 
was very efficient for increasing edentulous 
ridge height compared to the use of autogenous 
bone (54).  
Arora, et al. (2010) in a systematic review stated 
that using PRP had no positive effect on the 
outcome of sinus grafting despite what is said 
theoretically regarding its effect on hard and soft 
tissues. But, working with graft materials is 
enhanced by using PRP (55).  
DePoi, et al. (2008) used PRP for treatment of 
anoroantral fistula formed following sinus 
grafting and reported successful results (56).  
Bae, et al, (2011) in a meta-analysis evaluated 
the efficacy of PRP for sinus grafting and 
demonstrated that implant success in the two 
groups of control (sinus grafting without PRP) 
and intervention (sinus grafting plus PRP) was 
not significantly different. New bone formation 
in the intervention group was significantly 
greater than in the control group. Bone-implant 
contact was not significantly different in the two 
groups (63). In another study, PRP was used in 
conjunction with piezoelectric alveolar ridge 
expansion technique (64). Lee, et al. (2007) used 
PRP for treatment of osteonecrosis due to the 
administration of oral bisphosphonates in 2 
patients. The treatment outcome in both patients 
was successful considering complete resolution 




PRP is widely used in surgical procedures for 
regeneration of hard and soft tissues. Using this 
gel in conjunction with graft materials enhances 
their application. Many studies have reported 
improved quality and quantity of newly formed 
bone due to its application. However, results in 
this respect are controversial.  
Longitudinal studies are required to assess the 
efficacy of clinical application of PRP alone and 
in conjunction with graft materials. Meta-
analyses are also recommended to determine the 
prognosis of regenerative procedures. 
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